Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin.
Saved in:
| Title: | Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin. |
|---|---|
| Authors: | Hollander P; a Baylor Endocrine Center , Dallas , TX , USA., Hill J; b Merck & Co. Inc. , Kenilworth , NJ , USA., Johnson J; b Merck & Co. Inc. , Kenilworth , NJ , USA., Wei Jiang Z; c MSD R&D (China) Co. Ltd , Beijing , China., Golm G; b Merck & Co. Inc. , Kenilworth , NJ , USA., Huyck S; b Merck & Co. Inc. , Kenilworth , NJ , USA., Terra SG; d Pfizer Inc. , Andover , MA , USA., Mancuso JP; e Pfizer Inc. , Groton , CT , USA., Engel SS; b Merck & Co. Inc. , Kenilworth , NJ , USA., Lauring B; f formerly of Merck & Co. Inc. , Kenilworth , NJ , USA.; g Currently at Takeda Pharmaceuticals , Cambridge , MA , USA., Liu J; b Merck & Co. Inc. , Kenilworth , NJ , USA. |
| Source: | Current medical research and opinion [Curr Med Res Opin] 2019 Aug; Vol. 35 (8), pp. 1335-1343. Date of Electronic Publication: 2019 Mar 25. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Informa Healthcare Country of Publication: England NLM ID: 0351014 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-4877 (Electronic) Linking ISSN: 03007995 NLM ISO Abbreviation: Curr Med Res Opin Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1473-4877 |
|---|---|
| DOI: | 10.1080/03007995.2019.1583450 |
